Danaher Co. (NYSE:DHR) Shares Acquired by Oakworth Capital Inc.

Oakworth Capital Inc. increased its holdings in shares of Danaher Co. (NYSE:DHR) by 30.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 458 shares of the conglomerate’s stock after purchasing an additional 106 shares during the period. Oakworth Capital Inc.’s holdings in Danaher were worth $114,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Wellington Management Group LLP boosted its position in Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the period. Capital International Investors increased its holdings in shares of Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Danaher in the 4th quarter valued at $1,752,382,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.0 %

NYSE:DHR traded down $0.01 on Friday, reaching $269.32. The company’s stock had a trading volume of 1,746,456 shares, compared to its average volume of 2,862,712. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The stock has a 50 day moving average price of $257.69 and a 200 day moving average price of $253.51. The firm has a market cap of $199.48 billion, a price-to-earnings ratio of 45.65, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm posted $2.05 earnings per share. Danaher’s revenue was down 2.9% compared to the same quarter last year. On average, equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,707 shares of company stock valued at $10,786,944. 11.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Citigroup upped their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Stifel Nicolaus lifted their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Bank of America upped their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada lifted their target price on shares of Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $276.88.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.